Literature DB >> 30466748

Can one target T-cell ALL?

Adolfo Ferrando1.   

Abstract

Progress in our understanding of the central genes, pathways, and mechanisms in the pathobiology of T-cell acute lymphoblastic leukemia (T-ALL) has identified key drivers of the disease, opening new opportunities for therapy. Drugs targeting highly prevalent genetic alterations in NOTCH1 and CDKN2A are being explored, and multiple other targets with readily available therapeutic agents, and immunotherapies are being investigated. The molecular basis of T-ALL is reviewed here and potential targets and therapeutic targets discussed.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CDKN2A; Chimeric antigen receptor; GSI; Gamma secretase inhibitor; JAK/STAT; Mutations; NOTCH1; NT5C2CAR; NUP214-ABL1; PTEN; T-ALL; T-cell acute lymphoblastic leukemia

Mesh：

Substances：

Year:  2018        PMID： 30466748      PMCID： PMC6294319          DOI： 10.1016/j.beha.2018.10.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  56 in total

1.  Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.

Authors:  C Graux; J Cools; C Melotte; H Quentmeier; A Ferrando; R Levine; J R Vermeesch; M Stul; B Dutta; N Boeckx; A Bosly; P Heimann; A Uyttebroeck; N Mentens; R Somers; R A F MacLeod; H G Drexler; A T Look; D G Gilliland; L Michaux; P Vandenberghe; I Wlodarska; Peter Marynen; Anne Hagemeijer
Journal:  Nat Genet       Date:  2004-09-12       Impact factor: 38.330

2.  Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.

Authors:  Yana Pikman; Gabriela Alexe; Giovanni Roti; Amy Saur Conway; Andrew Furman; Emily S Lee; Andrew E Place; Sunkyu Kim; Chitra Saran; Rebecca Modiste; David M Weinstock; Marian Harris; Andrew L Kung; Lewis B Silverman; Kimberly Stegmaier
Journal:  Clin Cancer Res       Date:  2016-11-09       Impact factor: 12.531

3.  NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse.

Authors:  Sarah Clarke; John O'Reilly; Giuliana Romeo; Julian Cooney
Journal:  Leuk Res       Date:  2011-04-13       Impact factor: 3.156

4.  Deficient T cell fate specification in mice with an induced inactivation of Notch1.

Authors:  F Radtke; A Wilson; G Stark; M Bauer; J van Meerwijk; H R MacDonald; M Aguet
Journal:  Immunity       Date:  1999-05       Impact factor: 31.745

5.  Targeted cellular immunotherapy for T cell malignancies.

Authors:  Teresa Palomero; Adolfo Ferrando
Journal:  Nat Med       Date:  2017-12-07       Impact factor: 53.440

6.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; Donna S Neuberg; Jane Staunton; Mignon L Loh; Christine Huard; Susana C Raimondi; Fred G Behm; Ching Hon Pui; James R Downing; D Gary Gilliland; Eric S Lander; Todd R Golub; A Thomas Look
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

7.  Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.

Authors:  Amélie Trinquand; Aline Tanguy-Schmidt; Raouf Ben Abdelali; Jérôme Lambert; Kheira Beldjord; Etienne Lengliné; Noémie De Gunzburg; Dominique Payet-Bornet; Ludovic Lhermitte; Hossein Mossafa; Véronique Lhéritier; Jonathan Bond; Françoise Huguet; Agnès Buzyn; Thibaud Leguay; Jean-Yves Cahn; Xavier Thomas; Yves Chalandon; André Delannoy; Caroline Bonmati; Sebastien Maury; Bertrand Nadel; Elizabeth Macintyre; Norbert Ifrah; Hervé Dombret; Vahid Asnafi
Journal:  J Clin Oncol       Date:  2013-10-28       Impact factor: 44.544

8.  Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.

Authors:  Kathleen Cullion; Kyle M Draheim; Nicole Hermance; Jennifer Tammam; Vishva M Sharma; Christopher Ware; George Nikov; Veena Krishnamoorthy; Pradip K Majumder; Michelle A Kelliher
Journal:  Blood       Date:  2009-02-26       Impact factor: 22.113

9.  Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.

Authors:  Julia A Meyer; Jinhua Wang; Laura E Hogan; Jun J Yang; Smita Dandekar; Jay P Patel; Zuojian Tang; Paul Zumbo; Sheng Li; Jiri Zavadil; Ross L Levine; Timothy Cardozo; Stephen P Hunger; Elizabeth A Raetz; William E Evans; Debra J Morrison; Christopher E Mason; William L Carroll
Journal:  Nat Genet       Date:  2013-02-03       Impact factor: 38.330

10.  Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.

Authors:  Pedro J Real; Valeria Tosello; Teresa Palomero; Mireia Castillo; Eva Hernando; Elisa de Stanchina; Maria Luisa Sulis; Kelly Barnes; Catherine Sawai; Irene Homminga; Jules Meijerink; Iannis Aifantis; Giuseppe Basso; Carlos Cordon-Cardo; Walden Ai; Adolfo Ferrando
Journal:  Nat Med       Date:  2008-12-21       Impact factor: 53.440
View more
  8 in total

1.  How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children.

Authors:  David T Teachey; David O'Connor
Journal:  Blood       Date:  2020-01-16       Impact factor: 22.113

2.  Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.

Authors:  Llucia Albertí-Servera; Sofie Demeyer; Inge Govaerts; Toon Swings; Jolien De Bie; Olga Gielen; Marco Brociner; Lucienne Michaux; Johan Maertens; Anne Uyttebroeck; Kim De Keersmaecker; Nancy Boeckx; Heidi Segers; Jan Cools
Journal:  Blood       Date:  2021-02-11       Impact factor: 22.113

Review 3.  The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.

Authors:  Marta Weronika Lato; Anna Przysucha; Sylwia Grosman; Joanna Zawitkowska; Monika Lejman
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

4.  Genetic Heterogeneity of Esophageal Squamous Cell Carcinoma with Inherited Family History.

Authors:  Wenwu He; Xuefeng Leng; Yanyu Yang; Lin Peng; Yang Shao; Xue Li; Yongtao Han
Journal:  Onco Targets Ther       Date:  2020-09-03       Impact factor: 4.147

Review 5.  The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response.

Authors:  Alberto M Martelli; Francesca Paganelli; Antonietta Fazio; Chiara Bazzichetto; Fabiana Conciatori; James A McCubrey
Journal:  Cancers (Basel)       Date:  2019-05-06       Impact factor: 6.639

6.  Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia.

Authors:  Panpan Feng; Dawei Chen; Xia Wang; Yanxia Li; Zhenyu Li; Boya Li; Yupeng Zhang; Wei Li; Jingru Zhang; Jingjing Ye; Baobing Zhao; Jingxin Li; Chunyan Ji
Journal:  Leukemia       Date:  2022-08-01       Impact factor: 12.883

7.  NOTCH-ing up nucleotide metabolism in T-cell acute lymphoblastic leukemia.

Authors:  Andrew Volk
Journal:  Commun Biol       Date:  2021-06-29

8.  More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.

Authors:  Pilar López-Nieva; Laura González-Sánchez; María Ángeles Cobos-Fernández; Raúl Córdoba; Javier Santos; José Fernández-Piqueras
Journal:  Oncologist       Date:  2020-11-26       Impact factor: 5.837
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.